Insights from an academic endeavor into central nervous system drug discovery  

作　　者：Lieve van Veggel An M.Voets Tim Vanmierlo Rudy Schreiber 

机构地区：[1]BIOMED Biomedical Research Institute,Faculty of Medicine and Life Sciences,Hasselt University,Hasselt,Belgium [2]Department of Psychiatry and Neuropsychology,Division of Translational Neuroscience,European Graduate School of Neuroscience,School for Mental Health and Neuroscience,Maastricht University,Maastricht,The Netherlands [3]Section of Psychopharmacology,Neuropsychology and Psychopharmacology,Faculty of Psychology and Neuroscience,Maastricht University,Maastricht,The Netherlands [4]University MS Center(UMSC),Hasselt-Pelt,Belgium

出　　处：《Neural Regeneration Research》2025年第6期1717-1718,共2页中国神经再生研究（英文版）

基　　金：funded by the FWO(1S34321N);the Fondation Charcot Stichting(to TV and RS)。

摘　　要：Historically,"big pharma"did most central nervous system drug discovery R&D in-house.Yet,in modern times their"management reductionism"resulted in disappointing pipelines and pharma resided to(late)development,regulatory approval,and marketing(Thong,2015).This had significant consequences for financing and executing research,resulting in a larger role for funding by governments and patient-organizations and a shift of research to academia(Mazzucato,2013).

关 键 词：ACADEMIC APPROVAL consequences 

分 类 号：R914[医药卫生—药物化学]